Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

New blood test developed for early Alzheimer's diagnosis

April 24, 2019

Topline results from phase III study of tanezumab in osteoarthritis

April 23, 2019

Zhejiang Hisun Pharmaceutical divulges new SCN9A blockers

April 23, 2019

Yale scientists restore function in pig brains post-mortem

April 18, 2019

5-HT7/5-HT1A partial agonist FPT shows promise in model of fragile X syndrome

April 18, 2019

Wave Life Sciences presents phase I data and updates on development of suvodirsen

April 17, 2019

Cortexyme launches phase II/III study of COR-388 in subjects with Alzheimer's disease

April 16, 2019

MediciNova moves forward with a phase III study of MN-166 in ALS

April 16, 2019

Hansa receives ethics and regulatory clearance to initiate phase II study of imlifidase in GBS

April 16, 2019

Synapse formation important for ketamine durability

April 16, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.